Loading…

Repurposing fusion inhibitor peptide against SARS‐CoV‐2

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously evolving. Although several vaccines were approved, this pandemic is still a major threat to public life. Till date, no established therapies are available against SARS‐CoV‐2. Peptide inhibitors hold great promise for this v...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Computational Chemistry 2021-12, Vol.42 (32), p.2283-2293
Main Authors: Efaz, Faiyaz Md, Islam, Shafiqul, Talukder, Shafi Ahmad, Akter, Shaila, Tashrif, Md. Zakaria, Ali, Md. Ackas, Sufian, Md. Abu, Parves, Md. Rimon, Islam, Md. Jahirul, Halim, Mohammad A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3
cites cdi_FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3
container_end_page 2293
container_issue 32
container_start_page 2283
container_title Journal of Computational Chemistry
container_volume 42
creator Efaz, Faiyaz Md
Islam, Shafiqul
Talukder, Shafi Ahmad
Akter, Shaila
Tashrif, Md. Zakaria
Ali, Md. Ackas
Sufian, Md. Abu
Parves, Md. Rimon
Islam, Md. Jahirul
Halim, Mohammad A.
description Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously evolving. Although several vaccines were approved, this pandemic is still a major threat to public life. Till date, no established therapies are available against SARS‐CoV‐2. Peptide inhibitors hold great promise for this viral pathogen due to their efficacy, safety, and specificity. In this study, seventeen antiviral peptides which were known to inhibit SARS‐CoV‐1 are collected and computationally screened against heptad repeat 1 (HR1) of the SARS‐CoV‐2 spike protein (S2). Out of 17 peptides, Fp13 and Fp14 showed better binding affinity toward HR1 compared to a control peptide EK1 (a modified pan‐coronavirus fusion inhibitor) in molecular docking. To explore the time‐dependent interactions of the fusion peptide with HR1, molecular dynamics simulation was performed incorporating lipid membrane. During 100 ns MD simulation, structural and energy parameters of Fp13‐HR1 and Fp14‐HR1 complexes demonstrated lower fluctuations compared to the control EK1‐HR1 complex. Furthermore, principal component analysis and free energy landscape study revealed that these two peptides (Fp13 and Fp14) strongly bind to the HR1 with higher affinity than that of control EK1. Tyr917, Asn919, Gln926, lys933, and Gln949 residues in HR1 protein were found to be crucial residues for peptide interaction. Notably, Fp13, Fp14 showed reasonably better binding free energy and hydrogen bond contribution than that of EK1. Taken together, Fp13 and Fp14 peptides may be highly specific for HR1 which can potentially prevent the formation of the fusion core and could be further developed as therapeutics for treatment or prophylaxis of SARS‐CoV‐2 infection. SARS CoV‐2 uses spike protein for binding with host cell membrane to entry. Spike protein consists of two domains such as S1 and S2. When S1 domain binds with host cell receptor ACE2, it is cleaved by host cell protease enzyme TMPRSS2. After cleavage of S1, S2 is inserted to the host cell membrane surface. Mainly HR1 and HR2 protein of S2 of SARS CoV‐2 spike protein are responsible for fusion process. After the insertion of S2 on host cell membrane, HR1 and HR2 are attached together, forming a fusion core to bring virus and cell membrane in close proximity to mediate fusion process. The outcome of this computational study displays that the attachment of peptide with HR1 protein can be good strategy to inhibit the formation of fusion core which may lead disruption of f
doi_str_mv 10.1002/jcc.26758
format article
fullrecord <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_proquest_journals_2597445313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2597445313</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3</originalsourceid><addsrcrecordid>eNp90L9OwzAQBnALgUQpDLxBJCaGtOc4dmwxoYi_qoTUAmKzXMcurkoc7ESoG4_AM_IkBMIKy93y--6kD6FjDBMMkE3XWk8yVlC-g0YYBEsFL5520QiwyFLOKN5HBzGuAYBQlo_Q2dw0XWh8dPUqsV10vk5c_eyWrvUhaUzTusokaqVcHdtkcT5ffL5_lP6xn9kh2rNqE83R7x6jh8uL-_I6nd1d3ZTns1QTQXhK7FIRKDRTWJNKKcOoJQWoTBfAjTIVUE54xXKrzVJYjAUTlllagcBckIqM0clwtwn-tTOxlWvfhbp_KTMqijynBJP_VcGBkFzkvTodlA4-xmCsbIJ7UWErMcjvBmXfoPxpsLfTwb65jdn-DeVtWQ6JL2xPcms</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2578033494</pqid></control><display><type>article</type><title>Repurposing fusion inhibitor peptide against SARS‐CoV‐2</title><source>Coronavirus Research Database</source><creator>Efaz, Faiyaz Md ; Islam, Shafiqul ; Talukder, Shafi Ahmad ; Akter, Shaila ; Tashrif, Md. Zakaria ; Ali, Md. Ackas ; Sufian, Md. Abu ; Parves, Md. Rimon ; Islam, Md. Jahirul ; Halim, Mohammad A.</creator><creatorcontrib>Efaz, Faiyaz Md ; Islam, Shafiqul ; Talukder, Shafi Ahmad ; Akter, Shaila ; Tashrif, Md. Zakaria ; Ali, Md. Ackas ; Sufian, Md. Abu ; Parves, Md. Rimon ; Islam, Md. Jahirul ; Halim, Mohammad A.</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously evolving. Although several vaccines were approved, this pandemic is still a major threat to public life. Till date, no established therapies are available against SARS‐CoV‐2. Peptide inhibitors hold great promise for this viral pathogen due to their efficacy, safety, and specificity. In this study, seventeen antiviral peptides which were known to inhibit SARS‐CoV‐1 are collected and computationally screened against heptad repeat 1 (HR1) of the SARS‐CoV‐2 spike protein (S2). Out of 17 peptides, Fp13 and Fp14 showed better binding affinity toward HR1 compared to a control peptide EK1 (a modified pan‐coronavirus fusion inhibitor) in molecular docking. To explore the time‐dependent interactions of the fusion peptide with HR1, molecular dynamics simulation was performed incorporating lipid membrane. During 100 ns MD simulation, structural and energy parameters of Fp13‐HR1 and Fp14‐HR1 complexes demonstrated lower fluctuations compared to the control EK1‐HR1 complex. Furthermore, principal component analysis and free energy landscape study revealed that these two peptides (Fp13 and Fp14) strongly bind to the HR1 with higher affinity than that of control EK1. Tyr917, Asn919, Gln926, lys933, and Gln949 residues in HR1 protein were found to be crucial residues for peptide interaction. Notably, Fp13, Fp14 showed reasonably better binding free energy and hydrogen bond contribution than that of EK1. Taken together, Fp13 and Fp14 peptides may be highly specific for HR1 which can potentially prevent the formation of the fusion core and could be further developed as therapeutics for treatment or prophylaxis of SARS‐CoV‐2 infection. SARS CoV‐2 uses spike protein for binding with host cell membrane to entry. Spike protein consists of two domains such as S1 and S2. When S1 domain binds with host cell receptor ACE2, it is cleaved by host cell protease enzyme TMPRSS2. After cleavage of S1, S2 is inserted to the host cell membrane surface. Mainly HR1 and HR2 protein of S2 of SARS CoV‐2 spike protein are responsible for fusion process. After the insertion of S2 on host cell membrane, HR1 and HR2 are attached together, forming a fusion core to bring virus and cell membrane in close proximity to mediate fusion process. The outcome of this computational study displays that the attachment of peptide with HR1 protein can be good strategy to inhibit the formation of fusion core which may lead disruption of fusion process of SARS CoV‐2.</description><identifier>ISSN: 0192-8651</identifier><identifier>EISSN: 1096-987X</identifier><identifier>DOI: 10.1002/jcc.26758</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Affinity ; antiviral peptides ; Binding ; Coronaviruses ; Free energy ; free energy landscape ; fusion core ; heptad repeat 1 ; Hydrogen bonds ; Hydrogen-based energy ; Inhibitors ; Lipids ; Molecular docking ; Molecular dynamics ; molecular dynamics simulation ; Peptides ; Principal components analysis ; Prophylaxis ; Proteins ; Residues ; SARS‐CoV‐2 ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases</subject><ispartof>Journal of Computational Chemistry, 2021-12, Vol.42 (32), p.2283-2293</ispartof><rights>2021 Wiley Periodicals LLC.</rights><rights>2021. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3</citedby><cites>FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3</cites><orcidid>0000-0002-1698-7044</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2578033494?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,38516,43895</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2578033494?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc></links><search><creatorcontrib>Efaz, Faiyaz Md</creatorcontrib><creatorcontrib>Islam, Shafiqul</creatorcontrib><creatorcontrib>Talukder, Shafi Ahmad</creatorcontrib><creatorcontrib>Akter, Shaila</creatorcontrib><creatorcontrib>Tashrif, Md. Zakaria</creatorcontrib><creatorcontrib>Ali, Md. Ackas</creatorcontrib><creatorcontrib>Sufian, Md. Abu</creatorcontrib><creatorcontrib>Parves, Md. Rimon</creatorcontrib><creatorcontrib>Islam, Md. Jahirul</creatorcontrib><creatorcontrib>Halim, Mohammad A.</creatorcontrib><title>Repurposing fusion inhibitor peptide against SARS‐CoV‐2</title><title>Journal of Computational Chemistry</title><description>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously evolving. Although several vaccines were approved, this pandemic is still a major threat to public life. Till date, no established therapies are available against SARS‐CoV‐2. Peptide inhibitors hold great promise for this viral pathogen due to their efficacy, safety, and specificity. In this study, seventeen antiviral peptides which were known to inhibit SARS‐CoV‐1 are collected and computationally screened against heptad repeat 1 (HR1) of the SARS‐CoV‐2 spike protein (S2). Out of 17 peptides, Fp13 and Fp14 showed better binding affinity toward HR1 compared to a control peptide EK1 (a modified pan‐coronavirus fusion inhibitor) in molecular docking. To explore the time‐dependent interactions of the fusion peptide with HR1, molecular dynamics simulation was performed incorporating lipid membrane. During 100 ns MD simulation, structural and energy parameters of Fp13‐HR1 and Fp14‐HR1 complexes demonstrated lower fluctuations compared to the control EK1‐HR1 complex. Furthermore, principal component analysis and free energy landscape study revealed that these two peptides (Fp13 and Fp14) strongly bind to the HR1 with higher affinity than that of control EK1. Tyr917, Asn919, Gln926, lys933, and Gln949 residues in HR1 protein were found to be crucial residues for peptide interaction. Notably, Fp13, Fp14 showed reasonably better binding free energy and hydrogen bond contribution than that of EK1. Taken together, Fp13 and Fp14 peptides may be highly specific for HR1 which can potentially prevent the formation of the fusion core and could be further developed as therapeutics for treatment or prophylaxis of SARS‐CoV‐2 infection. SARS CoV‐2 uses spike protein for binding with host cell membrane to entry. Spike protein consists of two domains such as S1 and S2. When S1 domain binds with host cell receptor ACE2, it is cleaved by host cell protease enzyme TMPRSS2. After cleavage of S1, S2 is inserted to the host cell membrane surface. Mainly HR1 and HR2 protein of S2 of SARS CoV‐2 spike protein are responsible for fusion process. After the insertion of S2 on host cell membrane, HR1 and HR2 are attached together, forming a fusion core to bring virus and cell membrane in close proximity to mediate fusion process. The outcome of this computational study displays that the attachment of peptide with HR1 protein can be good strategy to inhibit the formation of fusion core which may lead disruption of fusion process of SARS CoV‐2.</description><subject>Affinity</subject><subject>antiviral peptides</subject><subject>Binding</subject><subject>Coronaviruses</subject><subject>Free energy</subject><subject>free energy landscape</subject><subject>fusion core</subject><subject>heptad repeat 1</subject><subject>Hydrogen bonds</subject><subject>Hydrogen-based energy</subject><subject>Inhibitors</subject><subject>Lipids</subject><subject>Molecular docking</subject><subject>Molecular dynamics</subject><subject>molecular dynamics simulation</subject><subject>Peptides</subject><subject>Principal components analysis</subject><subject>Prophylaxis</subject><subject>Proteins</subject><subject>Residues</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><issn>0192-8651</issn><issn>1096-987X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNp90L9OwzAQBnALgUQpDLxBJCaGtOc4dmwxoYi_qoTUAmKzXMcurkoc7ESoG4_AM_IkBMIKy93y--6kD6FjDBMMkE3XWk8yVlC-g0YYBEsFL5520QiwyFLOKN5HBzGuAYBQlo_Q2dw0XWh8dPUqsV10vk5c_eyWrvUhaUzTusokaqVcHdtkcT5ffL5_lP6xn9kh2rNqE83R7x6jh8uL-_I6nd1d3ZTns1QTQXhK7FIRKDRTWJNKKcOoJQWoTBfAjTIVUE54xXKrzVJYjAUTlllagcBckIqM0clwtwn-tTOxlWvfhbp_KTMqijynBJP_VcGBkFzkvTodlA4-xmCsbIJ7UWErMcjvBmXfoPxpsLfTwb65jdn-DeVtWQ6JL2xPcms</recordid><startdate>20211215</startdate><enddate>20211215</enddate><creator>Efaz, Faiyaz Md</creator><creator>Islam, Shafiqul</creator><creator>Talukder, Shafi Ahmad</creator><creator>Akter, Shaila</creator><creator>Tashrif, Md. Zakaria</creator><creator>Ali, Md. Ackas</creator><creator>Sufian, Md. Abu</creator><creator>Parves, Md. Rimon</creator><creator>Islam, Md. Jahirul</creator><creator>Halim, Mohammad A.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>COVID</scope><scope>JQ2</scope><orcidid>https://orcid.org/0000-0002-1698-7044</orcidid></search><sort><creationdate>20211215</creationdate><title>Repurposing fusion inhibitor peptide against SARS‐CoV‐2</title><author>Efaz, Faiyaz Md ; Islam, Shafiqul ; Talukder, Shafi Ahmad ; Akter, Shaila ; Tashrif, Md. Zakaria ; Ali, Md. Ackas ; Sufian, Md. Abu ; Parves, Md. Rimon ; Islam, Md. Jahirul ; Halim, Mohammad A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Affinity</topic><topic>antiviral peptides</topic><topic>Binding</topic><topic>Coronaviruses</topic><topic>Free energy</topic><topic>free energy landscape</topic><topic>fusion core</topic><topic>heptad repeat 1</topic><topic>Hydrogen bonds</topic><topic>Hydrogen-based energy</topic><topic>Inhibitors</topic><topic>Lipids</topic><topic>Molecular docking</topic><topic>Molecular dynamics</topic><topic>molecular dynamics simulation</topic><topic>Peptides</topic><topic>Principal components analysis</topic><topic>Prophylaxis</topic><topic>Proteins</topic><topic>Residues</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Efaz, Faiyaz Md</creatorcontrib><creatorcontrib>Islam, Shafiqul</creatorcontrib><creatorcontrib>Talukder, Shafi Ahmad</creatorcontrib><creatorcontrib>Akter, Shaila</creatorcontrib><creatorcontrib>Tashrif, Md. Zakaria</creatorcontrib><creatorcontrib>Ali, Md. Ackas</creatorcontrib><creatorcontrib>Sufian, Md. Abu</creatorcontrib><creatorcontrib>Parves, Md. Rimon</creatorcontrib><creatorcontrib>Islam, Md. Jahirul</creatorcontrib><creatorcontrib>Halim, Mohammad A.</creatorcontrib><collection>CrossRef</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Computer Science Collection</collection><jtitle>Journal of Computational Chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Efaz, Faiyaz Md</au><au>Islam, Shafiqul</au><au>Talukder, Shafi Ahmad</au><au>Akter, Shaila</au><au>Tashrif, Md. Zakaria</au><au>Ali, Md. Ackas</au><au>Sufian, Md. Abu</au><au>Parves, Md. Rimon</au><au>Islam, Md. Jahirul</au><au>Halim, Mohammad A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repurposing fusion inhibitor peptide against SARS‐CoV‐2</atitle><jtitle>Journal of Computational Chemistry</jtitle><date>2021-12-15</date><risdate>2021</risdate><volume>42</volume><issue>32</issue><spage>2283</spage><epage>2293</epage><pages>2283-2293</pages><issn>0192-8651</issn><eissn>1096-987X</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is continuously evolving. Although several vaccines were approved, this pandemic is still a major threat to public life. Till date, no established therapies are available against SARS‐CoV‐2. Peptide inhibitors hold great promise for this viral pathogen due to their efficacy, safety, and specificity. In this study, seventeen antiviral peptides which were known to inhibit SARS‐CoV‐1 are collected and computationally screened against heptad repeat 1 (HR1) of the SARS‐CoV‐2 spike protein (S2). Out of 17 peptides, Fp13 and Fp14 showed better binding affinity toward HR1 compared to a control peptide EK1 (a modified pan‐coronavirus fusion inhibitor) in molecular docking. To explore the time‐dependent interactions of the fusion peptide with HR1, molecular dynamics simulation was performed incorporating lipid membrane. During 100 ns MD simulation, structural and energy parameters of Fp13‐HR1 and Fp14‐HR1 complexes demonstrated lower fluctuations compared to the control EK1‐HR1 complex. Furthermore, principal component analysis and free energy landscape study revealed that these two peptides (Fp13 and Fp14) strongly bind to the HR1 with higher affinity than that of control EK1. Tyr917, Asn919, Gln926, lys933, and Gln949 residues in HR1 protein were found to be crucial residues for peptide interaction. Notably, Fp13, Fp14 showed reasonably better binding free energy and hydrogen bond contribution than that of EK1. Taken together, Fp13 and Fp14 peptides may be highly specific for HR1 which can potentially prevent the formation of the fusion core and could be further developed as therapeutics for treatment or prophylaxis of SARS‐CoV‐2 infection. SARS CoV‐2 uses spike protein for binding with host cell membrane to entry. Spike protein consists of two domains such as S1 and S2. When S1 domain binds with host cell receptor ACE2, it is cleaved by host cell protease enzyme TMPRSS2. After cleavage of S1, S2 is inserted to the host cell membrane surface. Mainly HR1 and HR2 protein of S2 of SARS CoV‐2 spike protein are responsible for fusion process. After the insertion of S2 on host cell membrane, HR1 and HR2 are attached together, forming a fusion core to bring virus and cell membrane in close proximity to mediate fusion process. The outcome of this computational study displays that the attachment of peptide with HR1 protein can be good strategy to inhibit the formation of fusion core which may lead disruption of fusion process of SARS CoV‐2.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/jcc.26758</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1698-7044</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0192-8651
ispartof Journal of Computational Chemistry, 2021-12, Vol.42 (32), p.2283-2293
issn 0192-8651
1096-987X
language eng
recordid cdi_proquest_journals_2597445313
source Coronavirus Research Database
subjects Affinity
antiviral peptides
Binding
Coronaviruses
Free energy
free energy landscape
fusion core
heptad repeat 1
Hydrogen bonds
Hydrogen-based energy
Inhibitors
Lipids
Molecular docking
Molecular dynamics
molecular dynamics simulation
Peptides
Principal components analysis
Prophylaxis
Proteins
Residues
SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2
Viral diseases
title Repurposing fusion inhibitor peptide against SARS‐CoV‐2
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T22%3A03%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repurposing%20fusion%20inhibitor%20peptide%20against%20SARS%E2%80%90CoV%E2%80%902&rft.jtitle=Journal%20of%20Computational%20Chemistry&rft.au=Efaz,%20Faiyaz%20Md&rft.date=2021-12-15&rft.volume=42&rft.issue=32&rft.spage=2283&rft.epage=2293&rft.pages=2283-2293&rft.issn=0192-8651&rft.eissn=1096-987X&rft_id=info:doi/10.1002/jcc.26758&rft_dat=%3Cproquest_COVID%3E2597445313%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3938-3fba307c6a1c3daae65f370a2c708eaed05838d64fceb9f11969f6f5d091893d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2578033494&rft_id=info:pmid/&rfr_iscdi=true